Lv7
3810 积分 2023-05-24 加入
Reporting and Outcomes of Brachytherapy for Gynecologic Reirradiation: A Systematic Review
13小时前
待确认
Five-Year Outcomes of Moderately Hypofractionated Whole Pelvic Radiation Therapy with Concurrent Chemotherapy and Image Guided High Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma
13小时前
已完结
Treatment strategies for oligometastatic and oligorecurrent epithelial ovarian cancer: a narrative review
13小时前
待确认
Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial
13小时前
已完结
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008
4天前
已完结
Optimal adjuvant therapy for early-stage cervical cancer (ESCC) with intermediate-risk factors: A target trial emulation of GOG-0263 based on the NCDB
4天前
已关闭
Gemcitabine intravesical system (Gem-iDRS) in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MIBC): SunRISe-2 final results
5天前
已关闭
Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial
7天前
已关闭
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study
17天前
已完结
1961O Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: A phase II, randomized study by the Hellenic GU Cancer Group
17天前
已完结
皖公网安备34019202002308
